Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study
Authors
Keywords
Breast cancer, Neoadjuvant chemotherapy, Predicting treatment outcome, Cellular response to anticancer drugs, Personalized medicine, in vitro diagnostics
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-07-14
DOI
10.1186/s12885-015-1491-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of the spheroid model complexity on drug response
- (2015) Oliver Ingo Hoffmann et al. JOURNAL OF BIOTECHNOLOGY
- Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
- (2014) E Alba et al. BRITISH JOURNAL OF CANCER
- Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment
- (2014) D. Herrmann et al. CARCINOGENESIS
- A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin
- (2014) Irene Brana et al. INVESTIGATIONAL NEW DRUGS
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Generation of multicellular tumor spheroids of breast cancer cells: How to go three-dimensional
- (2013) Anika Nagelkerke et al. ANALYTICAL BIOCHEMISTRY
- Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
- (2013) B. Gerber et al. ANNALS OF ONCOLOGY
- Tumorsphere assay provides more accurate prediction of in vivo responses to chemotherapeutics
- (2013) Soyoung Kim et al. BIOTECHNOLOGY LETTERS
- A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation
- (2013) L-B Weiswald et al. BRITISH JOURNAL OF CANCER
- HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
- (2013) Susan Dent et al. CANCER TREATMENT REVIEWS
- Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow
- (2013) Nadia Harbeck et al. CANCER TREATMENT REVIEWS
- Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44)
- (2013) Jens Huober et al. EUROPEAN JOURNAL OF CANCER
- Current approaches for neoadjuvant chemotherapy in breast cancer
- (2013) Roisin M. Connolly et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer
- (2013) Thomas Rutherford et al. GYNECOLOGIC ONCOLOGY
- Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
- (2013) Aman U Buzdar et al. LANCET ONCOLOGY
- Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
- (2013) Helena M Earl et al. LANCET ONCOLOGY
- New agents in locally advanced breast cancer
- (2013) Sheridan Wilson et al. Current Opinion in Supportive and Palliative Care
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
- (2012) Hatem A. Azim et al. CLINICAL CANCER RESEARCH
- Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice
- (2012) Domenico Angelucci et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- (2012) Laura J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy
- (2012) Geeta Mehta et al. JOURNAL OF CONTROLLED RELEASE
- Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
- (2012) Michael Untch et al. LANCET ONCOLOGY
- Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
- (2012) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
- PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery
- (2011) M. Untch et al. ANNALS OF ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays
- (2011) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer
- (2011) J. Kondo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array
- (2010) Yi-Chung Tung et al. ANALYST
- Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features
- (2010) Emilia Montagna et al. BREAST CANCER RESEARCH AND TREATMENT
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- (2008) Priya Rastogi et al. JOURNAL OF CLINICAL ONCOLOGY
- Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study
- (2008) G. von Minckwitz et al. JNCI-Journal of the National Cancer Institute
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started